REAGENT COMPOUNDS, COMPOSITIONS, KITS, AND METHODS FOR AMPLIFIED ASSAYS
The instant disclosure provides reagent compounds, and antibody and oligonucleotide reagents, for use in a variety of assays, including immunoassays and nucleic acid hybridizations. The reagent compounds comprise a bridging antigen or bridging oligonucleotide and a latent crosslinker moiety, such as a tyramide moiety. The bridging antigens are recognizable by the antibody of a corresponding antibody reagent with high affinity, and the bridging oligonucleotides are complementary to the oligonucleotide of a corresponding oligonucleotide reagent. The antibody reagents and oligonucleotide reagents also comprise a crosslinker activation agent, such as a peroxidase enzyme. Reaction of the reagent compounds with the crosslinker activation agent results in the amplification of signal in assays for target cellular markers, including cellular antigens and nucleic acids. Also provided are detectable antibodies specific for the bridging antigens, kits comprising the reagent compounds and antibody and oligonucleotide reagents, methods of signal amplification using the compounds and reagents of the disclosure, methods of preparation of the compounds and reagents, and compositions comprising the compounds and reagents.
1 - 174 . (canceled)
175 . A method for signal amplification comprising:
reacting a first antibody reagent with a target antigen in a biological sample, wherein the first antibody reagent specifically binds to the target antigen;
reacting the bound target antigen with a second antibody reagent, wherein the second antibody reagent comprises a second antibody specific for the first antibody and which comprises a crosslinker activation agent;
reacting the crosslinker activation agent with a bridging oligonucleotide linked to a latent crosslinker moiety, wherein the crosslinker activation agent activates the latent crosslinker moiety;
reacting the bridging oligonucleotide with a single-stranded circular nucleic acid template comprising a sequence complementary to the bridging oligonucleotide;
amplifying the sequence of the bridging oligonucleotide by rolling circle amplification in the presence of a DNA polymerase and deoxynucleotide triphosphates (dNTPs); and
detecting the amplified sequence by hybridizing a detectable oligonucleotide complementary to the amplified nucleic acid sequence.
176 . The method of claim 175 , wherein the crosslinker activation agent of the first antibody reagent comprises an enzyme.
177 . The method of claim 176 , wherein the enzyme is a peroxidase, an alkaline phosphatase, or a glucose oxidase.
178 . The method of claim 176 , wherein the enzyme is a peroxidase.
179 . The method of claim 178 , wherein the peroxidase is a horseradish peroxidase (HRP) or a soybean peroxidase.
180 . The method of claim 175 , wherein the target antigen is a cellular marker.
181 . The method of claim 175 , wherein the target antigen is a primary antibody specific for a cellular marker.
182 . The method of claim 175 , wherein the antibody of the first antibody reagent and the antibody of the second antibody reagent comprise antibodies from different species.
183 . The method of claim 175 , wherein the target antigen is a bridging antigen.
184 . The method of claim 175 , wherein the first antibody reagent has a dissociation constant of at most 1 nM.
185 . The method of claim 175 , wherein the bridging oligonucleotide comprises a detectable label.
186 . The method of claim 185 , wherein the detectable label is a fluorophore, an enzyme, an upconverting nanoparticle, a quantum dot, or a detectable hapten.
187 . The method of claim 185 , wherein the detectable label is a fluorophore.
188 . The method of claim 185 , wherein the detectable label is a peroxidase, an alkaline phosphatase, or a glucose oxidase.
189 . The method of claim 175 , the latent crosslinker moiety comprising a phenol moiety.
190 . The method of claim 175 , the latent crosslinker moiety being selected from tyramine, tyramide, tyrosine, and combinations thereof.
191 . The method of claim 175 , the latent crosslinker moiety being tyramide.
192 . The method of claim 175 , the bridging oligonucleotide comprising a nucleic acid selected from an LNA or PNA.
193 . The method of claim 175 , the bridging oligonucleotide comprising a locked nucleic acid.
194 . The method of claim 175 . the bridging oligonucleotide comprising a peptide nucleic acid.